Novo Nordisk's Oral Wegovy Launch Meets Supply Surge and Pricing Pressure as GLP-1 Competition Heats Up

The story of Novo Nordisk's recent expansion is a classic tale of supply struggling to catch up with explosive demand. The core commodity balance has been one of severe shortage, driven by a market that has grown at an unprecedented pace. The GLP-1 market itself is projected to balloon from $62.2 billion to $157.5 billion by 2035, a clear signal of long-term, structural growth. But the real pressure came in the near term. Prescriptions for these drugs surged 587% from 2019 to 2024, a staggering increase that started with the FDA's 2021 approval of Wegovy for weight loss. This demand explosion quickly overwhelmed manufacturing capacity, triggering a semaglutide shortage starting in March 2022 and lasting until February 2025.

The shortage was more than a simple inventory gap; it forced a parallel healthcare system into existence. With traditional channels blocked, federal law allowed compounding pharmacies to mass-produce copies, often distributed via direct-to-consumer telehealth platforms. Millions of patients turned to these cheaper, faster alternatives, revealing a critical vulnerability in the supply chain and a powerful patient-driven demand that could not be ignored. Novo's investment is a direct, reactive response to this period of acute imbalance.

Now, the company is launching a new demand catalyst just as its supply capacity is being expanded. In early January 2026, Novo launched an oral formulation of Wegovy, the first GLP-1 receptor agonist therapy approved for weight management in pill form. This is a significant product innovation that could further accelerate market penetration. Yet it also introduces a new supply challenge. The company's EUR 432 million ($502 million) investment in Ireland is explicitly aimed at building the tableting facility needed to produce this oral product, alongside future GLP-1 treatments. The construction, which has already begun, is slated to be completed by 2028.

The bottom line is that Novo's manufacturing push is necessary but inherently reactive. It is a strategic bet to close the gap created by years of surging demand, a gap that was so severe it forced a workaround through compounding. The launch of oral Wegovy ensures that demand will continue to evolve, and the company is now building the physical capacity to meet it. This is a supply response to a shifting demand landscape, where the next phase of growth requires not just more semaglutide, but a different form of it.

The Scale and Timing of the Supply Response

The scale of Novo Nordisk's manufacturing push is massive, reflecting the sheer magnitude of the demand it is trying to meet. The company is committing to a multi-year plan that exceeds DKK 100 billion for 2023–2025. This isn't a single project but a coordinated global build-out. A key component is the €432 million ($502 million) investment to expand its tabletting facility in Athlone, Ireland. Construction has already begun, with the expanded site expected to be finalized from the end of 2027 through to 2028. This specific project is designed to upgrade and boost capacity for oral GLP-1 products, a critical need given the launch of oral Wegovy.

This Irish investment fits into a broader, even larger strategy. The company is also building a new $3 billion facility in the Netherlands dedicated to oral solid medicines, a project that underscores its long-term commitment to this delivery form. These are not minor expansions; they are multi-billion-dollar bets on the future of oral GLP-1 therapy, with timelines stretching into the late 2020s.

The strategic focus, however, reveals a tension between ambition and caution. CEO Mike Doustdar has explicitly stated the company's goal is to scale its Wegovy pills country-by-country to avoid a shortage or a resurgence of compounding. This deliberate, phased rollout is a direct response to the past. The severe injectable shortage from 2022 to 2025 created a thriving parallel market of cheaper, compounded alternatives. By scaling slowly, Novo aims to prevent that scenario from repeating with its oral product.

The trade-off is clear. This strategy may limit near-term volume growth as the company prioritizes supply stability over rapid market capture. It is a calculated move to protect its premium brand and pricing power, but it also means the full commercial impact of the oral Wegovy launch will be realized over a longer horizon. The company is building the physical capacity to meet demand, but its go-to-market plan is designed to ensure that capacity is never outstripped again.

The New Headwinds: Pricing Pressure and Competitive Threat

The massive supply build-out is now meeting a new set of headwinds that could undermine the value of that increased capacity. Novo Nordisk itself has issued a stark warning: profits and sales could fall as much as 13% in 2026. This is a dramatic reversal from recent years of explosive growth and signals a market entering a new, more competitive phase. The company attributes this to heavy price pressure, especially in the U.S., and fierce competition. The guidance, which was far worse than the average analyst expectation of a 2% decline, has already triggered a sharp sell-off in its shares.

A key source of that pressure is the looming arrival of a major rival. Eli Lilly has reportedly built a $1.5 billion pre-launch inventory for its oral obesity drug, Orforglipron. This massive stockpile ensures Lilly can flood the market with supply immediately upon approval, which is expected in April. The move is a clear signal of intent to capture market share quickly, intensifying the battle for patients and prescribers. Novo's CEO has dismissed competition concerns, citing better clinical results for its pill, but the sheer scale of Lilly's preparedness sets a high bar.

Adding to the competitive pressure is the persistent operation of a parallel supply channel. Even after the semaglutide shortage ended in February 2025, some compounding pharmacies and direct-to-consumer telehealth platforms have continued producing generic versions of the drug. This creates a lower-cost alternative that pressures branded pricing and complicates Novo's efforts to maintain premium margins. The company is actively fighting back, having recently sued one such firm, but the parallel market remains a structural challenge.

The bottom line is that Novo's supply response is being met with a supply of its own-both from a new competitor and from a resilient, lower-cost alternative. The company's strategy of a slow, country-by-country rollout of its oral pill is a direct attempt to manage this new reality and avoid a repeat of the shortage-driven compounding boom. Yet, with pricing under pressure and a formidable rival poised to launch, the value of the expanded capacity is now in question. The commodity balance has shifted from a simple shortage to a complex battle for market share and price.

Catalysts and Risks: What to Watch for the Balance

The success of Novo's massive supply expansion hinges on a few critical near-term events and metrics. The company's strategy of a slow, country-by-country rollout of its oral Wegovy pill is designed to prevent a repeat of the past, but it also means the path to profitable growth will be measured in quarterly milestones.

First, investors must monitor the quarterly rollout itself. The initial U.S. launch in January has seen 246,000 people on the pill, a promising start. The key will be tracking whether this new oral volume cannibalizes injectable sales or grows the overall market. More importantly, watch for any signs of a resurgence in the parallel compounding market. Despite the official end of the semaglutide shortage, Novo continues to battle increased compounding of its drugs. If the company's slow rollout creates a perception of scarcity, it could inadvertently fuel that cheaper, alternative supply chain again, undermining premium pricing.

Second, regulatory progress is a key catalyst. While the U.S. approval is secured, the company has filed for approval in the European Union. The timing and outcome of that European review will determine the next phase of the rollout. Simultaneously, progress on the new Katwijk, Netherlands facility is a longer-term but critical indicator. This $3 billion plant is a major pillar of Novo's oral manufacturing strategy, and its construction schedule will signal the company's commitment to scaling beyond the Irish project.

The primary risk, however, is that increased supply meets heightened competition and pricing pressure. The company's own guidance for profits and sales to fall as much as 13% in 2026 is a stark warning. This decline is attributed to heavy price pressure, especially in the U.S., and fierce competition. The looming launch of Eli Lilly's oral drug, backed by a $1.5 billion pre-launch inventory, is the most immediate threat. If Lilly floods the market with supply in April as expected, it could trigger a price war that erodes margins across the board. In this scenario, Novo's expanded capacity could quickly become a liability, leading to a supply glut in a commodity-like GLP-1 market despite the initial shortage.

The bottom line is that the commodity balance is now in flux. The company has built the physical capacity to meet demand, but the value of that capacity is being tested by a new, more competitive reality. The coming quarters will show whether Novo's strategic rollout can navigate this turbulence to translate its supply build-out into sustainable, profitable growth.